- Home
- NXTC vs CCM Comparison
NXTC vs CCM Comparison
Compare NXTC & CCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- CCM
- Stock Information
- Founded
- NXTC 2015
- CCM 1997
- Country
- NXTC United States
- CCM China
- Employees
- NXTC N/A
- CCM N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- CCM Medical/Nursing Services
- Sector
- NXTC Health Care
- CCM Health Care
- Exchange
- NXTC Nasdaq
- CCM Nasdaq
- Market Cap
- NXTC 23.0M
- CCM 20.4M
- IPO Year
- NXTC 2019
- CCM 2009
- Fundamental
- Price
- NXTC $0.79
- CCM $4.70
- Analyst Decision
- NXTC Strong Buy
- CCM
- Analyst Count
- NXTC 2
- CCM 0
- Target Price
- NXTC $4.00
- CCM N/A
- AVG Volume (30 Days)
- NXTC 201.3K
- CCM 15.7K
- Earning Date
- NXTC 11-07-2024
- CCM 09-27-2024
- Dividend Yield
- NXTC N/A
- CCM N/A
- EPS Growth
- NXTC N/A
- CCM N/A
- EPS
- NXTC N/A
- CCM N/A
- Revenue
- NXTC N/A
- CCM $64,910,622.00
- Revenue This Year
- NXTC N/A
- CCM N/A
- Revenue Next Year
- NXTC N/A
- CCM N/A
- P/E Ratio
- NXTC N/A
- CCM N/A
- Revenue Growth
- NXTC N/A
- CCM N/A
- 52 Week Low
- NXTC $0.76
- CCM $3.80
- 52 Week High
- NXTC $2.57
- CCM $26.70
- Technical
- Relative Strength Index (RSI)
- NXTC 36.33
- CCM 47.65
- Support Level
- NXTC $0.76
- CCM $4.42
- Resistance Level
- NXTC $0.83
- CCM $5.09
- Average True Range (ATR)
- NXTC 0.07
- CCM 1.07
- MACD
- NXTC 0.01
- CCM -0.02
- Stochastic Oscillator
- NXTC 14.87
- CCM 11.67
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company operates cooperative centers across several provinces and administrative regions in China. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services, such as electroencephalography for the diagnosis of epilepsy, thermotherapy to increase the efficacy of and for pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound therapy for the treatment of cancer, stereotactic radiofrequency ablation for the treatment of Parkinson's Disease and refraction and tonometry for the diagnosis of ophthalmic conditions.